Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.

François-Xavier ChaletPierre-Philippe LuyetCristina RabasaCédric VaillantPaul SaskinAjay AhujaCitrome Leslie

Published in: Postgraduate medicine (2024)

Daridorexant 50 mg and 25 mg have a favorable benefit-risk ratio over 3 months. Daridorexant 50 mg demonstrated more robust (lower) NNT estimates versus placebo than daridorexant 25 mg.

Keyphrases

randomized controlled trial
clinical trial
depressive symptoms
sleep quality